close_game
close_game

Sputnik V 75% effective against Omicron: Vaccine developer

Updated On Jan 18, 2022 05:38 PM IST
  • The Sputnik V effectiveness against Omicron decreases by eight times but it is still enough for protection, Alexander Gintsburg said, adding that the effectiveness of other vaccines decreases by 21 times.
1 / 5
The head of Russia's Gamaleya Research Center, Alexander Gintsburg, on Tuesday said that the effectiveness of the Sputnik V Covid-19 vaccine against the Omicron coronavirus variant is 75 per cent. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

The head of Russia's Gamaleya Research Center, Alexander Gintsburg, on Tuesday said that the effectiveness of the Sputnik V Covid-19 vaccine against the Omicron coronavirus variant is 75 per cent.

2 / 5
"In the population, the effectiveness of the Sputnik V vaccine in relation to Omicron ... is 75 per cent," Alexander Gintsburg said in the Rossiya Segodnya press center. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

"In the population, the effectiveness of the Sputnik V vaccine in relation to Omicron ... is 75 per cent," Alexander Gintsburg said in the Rossiya Segodnya press center.

3 / 5
“Protection against Omicron increases to 100% if a person receives a Sputnik Light booster dose in six months but decreases to 56-57% if revaccination is not done," he further said about the booster dose. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

“Protection against Omicron increases to 100% if a person receives a Sputnik Light booster dose in six months but decreases to 56-57% if revaccination is not done," he further said about the booster dose.

4 / 5
Last week, Hyderabad-based biotechnology firm Bharat Biotech also said that the "Booster dose of Covaxin generated robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

Last week, Hyderabad-based biotechnology firm Bharat Biotech also said that the "Booster dose of Covaxin generated robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2.

5 / 5
"The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Bharat Biotech said in a statement. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

"The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Bharat Biotech said in a statement.

SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, November 28, 2023
Start 14 Days Free Trial Subscribe Now
Register Free and get Exciting Deals